TY - JOUR
T1 - Self-reported depressive symptom measures
T2 - Sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients
AU - Rush, A. John
AU - Trivedi, Madhukar H.
AU - Carmody, Thomas J.
AU - Ibrahim, Hisham H.
AU - Markowitz, John C.
AU - Keitner, Gabor I.
AU - Kornstein, Susan G.
AU - Arnow, Bruce
AU - Klein, Daniel N.
AU - Manber, Rachel
AU - Dunner, David L.
AU - Gelenberg, Alan J.
AU - Kocsis, James H.
AU - Nemeroff, Charles B.
AU - Fawcett, Jan
AU - Thase, Michael E.
AU - Russell, James M.
AU - Jody, Darlene N.
AU - Borian, Frances O.
AU - Keller, Martin B.
N1 - Funding Information:
This research was supported in part by grants from Bristol-Myers Squibb Company to the 12 participating sites, by NIMH Grant #MH68851, and by the Betty Jo Hay Distinguished Chair, the Rosewood Corporation Chair in Biomedical Science, and by the Sara E and Charles M Seay Center for Basic Research in Psychiatry. We thank Fast Word Inc., Dallas, Texas for secretarial assistance in preparation of this manuscript.
PY - 2005/2
Y1 - 2005/2
N2 - This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-1) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-1, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a ≥50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-1 score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-1), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-1), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR 16), 73% (PGI-1), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30 = 32%, QIDS-SR 16 = 28%, PGI-1 = 22%, HDRS17 = 30%), for CBASP (IDS-SR30 = 32%, QIDS-SR16 = 30%, PGI-1 = 21%, HDRS 17 = 32%), and for the combination (IDS-SR30 = 52%, QIDS-SR16 = 50%, PGI-1 = 25%, HDRS17 = 49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-1, as opposed to specific item-based ratings, provide less valid findings.
AB - This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-1) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-1, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a ≥50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-1 score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-1), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-1), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR 16), 73% (PGI-1), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30 = 32%, QIDS-SR 16 = 28%, PGI-1 = 22%, HDRS17 = 30%), for CBASP (IDS-SR30 = 32%, QIDS-SR16 = 30%, PGI-1 = 21%, HDRS 17 = 32%), and for the combination (IDS-SR30 = 52%, QIDS-SR16 = 50%, PGI-1 = 25%, HDRS17 = 49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-1, as opposed to specific item-based ratings, provide less valid findings.
KW - Chronic depression
KW - Nefazodone
KW - Psychotherapy
KW - Symptom measures
UR - http://www.scopus.com/inward/record.url?scp=19944430673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944430673&partnerID=8YFLogxK
U2 - 10.1038/sj.npp.1300614
DO - 10.1038/sj.npp.1300614
M3 - Article
C2 - 15578008
AN - SCOPUS:19944430673
SN - 0893-133X
VL - 30
SP - 405
EP - 416
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 2
ER -